Viking Global Opportunities Illiquid Investments Sub-Master LP is 10% Owner at Amylyx Pharmaceuticals, Inc. (AMLX). They have made 9 open-market trades across 8 companies since 2019, most recently 2025-01-31.
CIK 0001629482
5 open-market purchases totalling $81.2M since 2019, against 4 sales. Across 5 scored buys the stock is down 12.8% at ninety days, and 15.0 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 20% | 20% |
| Avg Move | +1.9% | -5.7% | -12.8% |
| Alpha | -7.1% | -5.8% | -15.0% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BBIO | SELL | 2025-01-31 | 2025-01-31 | $34.90 | $214.0M | -5.3% | -2.1% | +13.8% |
| APG | SELL | 2024-03-05 | 2024-03-07 | $34.25 | $206.1M | -3.5% | +0.3% | -4.9% |
| FDMT | SELL | 2024-01-04 | 2024-01-05 | $19.53 | $10.5M | -11.1% | +68.4% | +44.2% |
| AMLX | SELL | 2022-09-08 | 2022-09-09 | $29.80 | $83.4M | -3.9% | +12.4% | +21.9% |
| AMLX | BUY | 2022-01-11 | 2022-01-13 | $19.00 | $43.7M | -8.0% | -5.6% | -43.8% |
| RLYB | BUY | 2021-07-29 | 2021-08-02 | $13.00 | $10.5M | -6.4% | -28.3% | -0.7% |
| INBX | BUY | 2020-08-26 | 2020-08-28 | $18.92 | $6.8M | +28.1% | +7.1% | +7.1% |
| UROV | BUY | 2019-06-05 | 2019-06-06 | $8.02 | $52K | +4.5% | +2.1% | +13.9% |
| MYOV | BUY | 2019-06-04 | 2019-06-13 | $8.25 | $20.0M | +2.5% | -0.9% | -22.0% |
| UROV | BUY | 2019-05-16 | 2019-05-20 | $7.54 | $163K | -6.8% | -0.8% | -4.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| RLYB | 3,388,777 | $55.8M |
| FDMT | 4,247,914 | $51.6M |
| Total | $42.1B |
Shares reported on the most recent Form 4, priced at the 2025-01-31 close.